Banner
Late-Breaking Analysis In Hypertension Shows That Antihypertensive Treatments Differ In Their Ability To Preserve Lives

STOCKHOLM, August 30, 2010 /PRNewswire/ -- According to the results of a late-breaking analysis...

Clinical Results For New Treatment Of Bacterial Vaginosis Infection

The Swedish company Laccure AB recently got CE marking as a Class IIa medical device product for...

88 Percent Of UK Doctors Believe Whiplash Claims Are Exaggerated

AXA, a UK car insurer, has surveyed UK doctors as part of its ongoing campaign to understand the...

On Facebook, Women Are More Plentiful But Men Are Better Ad Targets

Global digital marketing companies Resolution Media and Kenshoo Social published a new report today...

User picture.
Anna OhldenRSS Feed of this column.

Media Relations Executive, PR Newswire Europe... Read More »

Blogroll

BRISTOL, England, December 10 /PRNewswire/ --

- The Creators of 'PaRappa the Rapper' Return With Music-Based Video Game

Majesco Entertainment Company (NASDAQ: COOL), an innovative provider of video games for the mass market, today announced a partnership with legendary multimedia musician and game designer, Masaya Matsuura, and famed New York artist Rodney Alan Greenblat, to develop and publish an original music-based video game scheduled for release in late 2008. Creators of the highly acclaimed, best-selling PaRappa the Rapper series, Matsuura and Greenblat will bring their engaging gameplay and distinctive art style to the Wii(TM) home video game system for the first time.

HALIFAX, Canada, December 10 /PRNewswire/ -- ImmunoVaccine Technologies Inc. (IVT), a Nova Scotia-based vaccine enhancement company, has signed a binding memorandum of understanding to acquire Immunotope Inc., a Pennsylvania-based biotechnology company developing immunotherapy products for the treatment and prevention of cancer and infectious diseases.

CALGARY, Canada, December 10 /PRNewswire/ --

- New Class of ApoA-I/HDL Drugs to Reverse Atherosclerosis Enters the Clinic

Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today that it has received approval by the US Food and Drug Administration (FDA) to initiate a Phase 1a clinical trial of oral RVX-208 in the USA. RVX-208 is a novel first-in-class small molecule that increases the production of ApoA-I and HDL. ApoA-I is regarded as the critical cardioprotective protein for the treatment of cardiovascular diseases.

AMSTERDAM, December 10 /PRNewswire/ -- BMEYE(TM) announced today that it has received 510(K) clearance from the U.S. Food and Drug Administration (FDA) to market Nexfin(TM), their newly developed line of safe, precise and easy to use hemodynamic monitors. The Nexfin(TM) monitors provide precise and easy to use continuous non-invasive blood pressure and cardiac output monitoring. BMEYE(TM) received CE market approval earlier this year.

MILPITAS, California, December 10 /PRNewswire/ --

SAN MATEO, California, December 10 /PRNewswire/ --

NetSuite Inc. today announced that the auction for its proposed initial public offering of its common stock has commenced. NetSuite announced that it expects the offering to price after the stock market closes on or about Wednesday, December 19, 2007.

(Logo: http://www.newscom.com/cgi-bin/prnh/20021024/SFTH024LOGO)

Credit Suisse Securities (USA) LLC will act as sole book-running manager for the offering, with W.R. Hambrecht + Co., LLC acting as co-manager. NetSuite will offer 6,200,000 shares of its common stock in the offering. NetSuite and the selling stockholders have also granted the underwriters a 30-day option to purchase up to an aggregate of 930,000 additional shares.